{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:38:48Z","timestamp":1783633128388,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejca.2023.04.013","type":"journal-article","created":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T01:33:08Z","timestamp":1682213588000},"page":"39-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours"],"prefix":"10.1016","volume":"188","author":[{"given":"Jorge","family":"Hernando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Roca-Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Garc\u00eda-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ruszniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Kulke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Garc\u00eda-Carbonero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Teule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Tafuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejca.2023.04.013_bib1","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/annonc\/mdz414","article-title":"Gender medicine and oncology: report and consensus of an ESMO workshop","volume":"30","author":"Wagner","year":"2019","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2023.04.013_bib2","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/jnci\/djac092","article-title":"An evaluation of sex- and gender-based analyses in oncology clinical trials","volume":"114","author":"Hall","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"10.1016\/j.ejca.2023.04.013_bib3","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials","volume":"40","author":"Unger","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.04.013_bib4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ejca.2023.04.013_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.957068","article-title":"Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications","volume":"12","author":"Lauricella","year":"2022","journal-title":"Front Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2023.04.013_bib6","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.04.013_bib7","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.04.013_bib8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.ejca.2023.04.013_bib9","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.ejca.2013.06.042","article-title":"Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)","volume":"49","author":"Castellano","year":"2013","journal-title":"Eur J Can"},{"key":"10.1016\/j.ejca.2023.04.013_bib10","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/annonc\/mdv252","article-title":"Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)","volume":"26","author":"Grande","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.04.013_bib11","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1200\/JCO.20.03368","article-title":"Lenvatinib in patients with advanced grade \u00bd pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE 1509)","volume":"39","author":"Capdevila","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.04.013_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41568-021-00348-y","article-title":"Sex disparities matter in cancer development and therapy","volume":"21","author":"Haupt","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2023.04.013_bib13","article-title":"Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry","volume":"7","author":"Gallego Plazas","year":"2022","journal-title":"ESMO Open"},{"issue":"13","key":"10.1016\/j.ejca.2023.04.013_bib14","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials","volume":"40","author":"Unger","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.04.013_bib15","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cncr.20878","article-title":"Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma","volume":"103","author":"Chansky","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.04.013_bib16","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2002.20.6.1491","article-title":"Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer","volume":"20","author":"Sloan","year":"2002","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2023.04.013_bib17","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2023.04.013_bib18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2217\/cer-2021-0205","article-title":"Sex-based differences in the outcome of patients with lung carcinoids","volume":"11","author":"Abdel-Rahman","year":"2022","journal-title":"J Comp Eff Res"},{"issue":"5","key":"10.1016\/j.ejca.2023.04.013_bib19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/MPA.0000000000001821","article-title":"Sex-based differences in prognosis of patients with gastroenteropancreatic-neuroendocrine neoplasms: a population-based study","volume":"50","author":"Abdel-Rahman","year":"2021","journal-title":"Pancreas"},{"issue":"9","key":"10.1016\/j.ejca.2023.04.013_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.tem.2020.02.010","article-title":"Pancreatic neuroendocrine neoplasms: does sex matter?","volume":"31","author":"Muscogiuri","year":"2020","journal-title":"Tren Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ejca.2023.04.013_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.6004\/jnccn.2021.7017","article-title":"Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms","volume":"20","author":"Al-Toubah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"10.1016\/j.ejca.2023.04.013_bib22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/RLU.0000000000004203","article-title":"Dose-limiting bone marrow toxicities after peptide receptor radionuclide therapy are more prevalent in women than in men","volume":"47","author":"Minczeles","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"Suppl. 3","key":"10.1016\/j.ejca.2023.04.013_bib23","article-title":"A phase II\/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107)","volume":"39","author":"Garcia-Carbonero","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2023.04.013_bib24","article-title":"Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET)","volume":"35","author":"Chan","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.04.013_bib25","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.04.013_bib26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ctrv.2018.06.019","article-title":"Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer","volume":"69","author":"Capdevila","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.ejca.2023.04.013_bib27","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3324\/haematol.2011.045666","article-title":"Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial","volume":"97","author":"Guilhot","year":"2012","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.ejca.2023.04.013_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12032-019-1263-3","article-title":"Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer","volume":"36","author":"Nagahama","year":"2019","journal-title":"Med Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2023.04.013_bib29","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1634\/theoncologist.2011-0439","article-title":"Variability of sorafenib toxicity and exposure over time: a pharmacokinetic\/pharmacodynamic analysis","volume":"17","author":"Boudou-Rouquette","year":"2012","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.ejca.2023.04.013_bib30","doi-asserted-by":"crossref","first-page":"ix122","DOI":"10.1016\/S0923-7534(20)32895-7","article-title":"Dysphonia as a previously unreported side effect of bevacizumab treatment in patients with metastatic breast cancer","volume":"23","author":"Radema","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.04.013_bib31","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1007\/s10637-009-9314-9","article-title":"Dysponia induced by vascular endothelium growth factor\/vascular endothelium growth factor receptor inhibitors","volume":"28","author":"Hartl","year":"2010","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1016\/j.ejca.2023.04.013_bib32","doi-asserted-by":"crossref","first-page":"e1969","DOI":"10.1210\/clinem\/dgac001","article-title":"Sexual dimorphism in small-intestine neuroendocrine tumors: lower prevalence of mesenteric disease in premenopausal women","volume":"107","author":"Blazevic","year":"2022","journal-title":"J Clin Endocrinol Metab"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2024.114061","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T08:38:03Z","timestamp":1695631083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923001995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":32,"alternative-id":["S0959804923001995"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.04.013","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejca.2024.114061","asserted-by":"object"}]},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}